{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:18:46Z","timestamp":1772119126544,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00228-023-03526-z","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:01:47Z","timestamp":1687262507000},"page":"1117-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C\u2009&gt;\u2009T (rs7668258) or UGT1A4*3 c.142\u00a0T\u2009&gt;\u2009G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-1699","authenticated-orcid":false,"given":"Nada","family":"Bo\u017eina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana \u0160u\u0161ak","family":"Spori\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva Klarica","family":"Domjanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana","family":"Ganoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livija","family":"\u0160imi\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Lovri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zrinka \u010colak","family":"Romi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljka Petelin","family":"Gad\u017ee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-1194","authenticated-orcid":false,"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"3526_CR1","unstructured":"Medicines.org.uk (2022) Lamictal Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/4228#. Accessed 25 Oct 2022"},{"key":"3526_CR2","doi-asserted-by":"crossref","unstructured":"Mitra-Ghosh T, Callisto SP, Lamba JK, Remmel RP, Birnbaum AK, Barbarino JM et al (2020) PharmGKB summary: lamotrigine pathway, pharmacokinetics and pharmacodynamics. Pharmacogenet Genom 30:81\u201390","DOI":"10.1097\/FPC.0000000000000397"},{"key":"3526_CR3","doi-asserted-by":"crossref","unstructured":"Patsalos PN (2016) Antiepileptic drug interactions. a clinical guide. 3rd ed. London, UK, Springer, pp. 55\u201359","DOI":"10.1007\/978-3-319-32909-3_11"},{"key":"3526_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.seizure.2020.07.014","volume":"82","author":"J Methaneethorn","year":"2020","unstructured":"Methaneethorn J, Leelakanok N (2020) Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses. Eur J Epilepsy 82:133\u2013147","journal-title":"Eur J Epilepsy"},{"key":"3526_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/DDDT.S154388","volume":"12","author":"A Reimers","year":"2018","unstructured":"Reimers A, Andsnes Berg J, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C (2018) Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Design Dev Ther 12:271\u2013280","journal-title":"Drug Design Dev Ther"},{"key":"3526_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1517\/17425255.2.6.1009","volume":"2","author":"V Biton","year":"2006","unstructured":"Biton V (2006) Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2:1009\u20131018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3526_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams A, Mackenzie PI, Dickson RG, Miner JO (2006) In vitro characterization of lamotrigine N2-glucuronication and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055\u20131062","journal-title":"Drug Metab Dispos"},{"key":"3526_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","volume":"52","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN (2013) Drug interactions with the newer antiepileptic drugs (AEDs) \u2013 part 1: pharmacokinetic and pharmacodynamics interactions between AEDs. Clin Pharmacokinet 52:927\u2013966","journal-title":"Clin Pharmacokinet"},{"key":"3526_CR9","unstructured":"FDA (2007) Lamictal. Clin Pharmacol Rev. https:\/\/www.fda.gov\/files\/drugs\/published\/020241s032_020764s025Lamotrigine Clinpharm BPCA (fda.gov). Accessed 21 Oct 2022"},{"key":"3526_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1517\/17425255.2014.952630","volume":"10","author":"O Bruhn","year":"2014","unstructured":"Bruhn O, Cascorbi I (2014) Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 10:10. https:\/\/doi.org\/10.1517\/17425255.2014.952630","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3526_CR11","unstructured":"UGT Nomenclature Committee (2023) UGT alleles nomenclature.  https:\/\/www.pharmacogenomics.pha.ulaval.ca\/ugt-alleles-nomenclature\/. Accessed 25 Oct 2022"},{"key":"3526_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/FPC.0b013e3283331637","volume":"19","author":"MO Benoit-Biancamano","year":"2009","unstructured":"Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogen Genom 19:945\u2013954","journal-title":"Pharmacogen Genom"},{"key":"3526_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000577","volume":"41","author":"T Suzuki","year":"2019","unstructured":"Suzuki T, Mihara K, Nagai G, Kagawa S, Nakamura A, Nemoto K, Kondo T (2019) Relationship between UGT1A4 and UGT2B7 polymorphisms and steady-state plasma concentrations of lamotrigine in patients with treatment-resistant depressive disorder receiving lamotrigine as augmentation therapy. Ther Drug Monit 41:86\u201390","journal-title":"Ther Drug Monit"},{"key":"3526_CR14","doi-asserted-by":"publisher","unstructured":"Petrenaite V, Ohman I, Thal Jantzen FP, Ekstrom L (2022) Effect of UGT1A4, UGT2B7, UGT2B15, UGT2B17 and ABCB1 polymorphisms on lamotrigine metabolism in Danish patients. Epilepsy Res 182:106897.\u00a0https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106897","DOI":"10.1016\/j.eplepsyres.2022.106897"},{"key":"3526_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1124\/dmd.118.082024","volume":"46","author":"C Xu","year":"2018","unstructured":"Xu C, Gao J, Zhang HF, Gao N, Guo YY, Fang Y et al (2018) Content and activities of UGT2B7 in human liver in vitro and predicted in vivo: a bottom-up approach. Drug Metab Dispos 46:1351\u20131359","journal-title":"Drug Metab Dispos"},{"key":"3526_CR16","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1124\/dmd.113.056630","volume":"42","author":"DG Hu","year":"2014","unstructured":"Hu DG, Meech R, Lu L, McKinnon RA, Mackenzie PI (2014) Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter. Drug Metab Dispos 42:854\u2013862","journal-title":"Drug Metab Dispos"},{"key":"3526_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clinbiochem.2006.01.002","volume":"39","author":"K Saito","year":"2006","unstructured":"Saito K, Moriya H, Sawaguchi T, Hayakawa T, Nakahara S, Goto A et al (2006) Haplotype analysis of UDP-glucuronosyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 39:303\u2013308","journal-title":"Clin Biochem"},{"key":"3526_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41397-020-0173-2","volume":"20","author":"A Ortega-Vazquez","year":"2020","unstructured":"Ortega-Vazquez A, Fricke-Galindo I, Dorado P, Jung-Cook H, Martinez-Juarez IE, Monroy-Jaramillo N et al (2020) Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine concentration in Mexican-Mestizo patients with epilepsy. Pharmacogenet J 20:845\u2013856","journal-title":"Pharmacogenet J"},{"key":"3526_CR19","doi-asserted-by":"crossref","unstructured":"Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N et al (2005) Genetic variations and haplotypes of UGT1A4 in Japanese population. Drug Metab Pharmacokinet 20:SNP13(144)-SNP20(151)","DOI":"10.2133\/dmpk.20.144"},{"key":"3526_CR20","first-page":"672","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucoronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Pharmacokinet 33:672\u2013675","journal-title":"Drug Metab Pharmacokinet"},{"key":"3526_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/hep.20131","volume":"39","author":"U Ehmer","year":"2004","unstructured":"Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP (2004) Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucoronosyltransferase UGT1A4. Hepatology 39:970\u2013977","journal-title":"Hepatology"},{"key":"3526_CR22","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s11033-012-2393-2","volume":"40","author":"M Lopez","year":"2013","unstructured":"Lopez M, Dorado P, Ortega A, Penas-Lledo E, Monroy N, Silva-Zolezzi I et al (2013) Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep 40:3187\u20133192","journal-title":"Mol Biol Rep"},{"key":"3526_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2217\/pgs.11.105","volume":"12","author":"J Zhou","year":"2011","unstructured":"Zhou J, Argikar UA, Remmel RP (2011) Functional analysis of UGT1A4P24T and UGT1A4L48V variant enzymes. Pharmacogenomics 12:1671\u20131679","journal-title":"Pharmacogenomics"},{"key":"3526_CR24","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","volume":"41","author":"A Reimers","year":"2016","unstructured":"Reimers A, Sjursen W, Helde G, Brodtkorb E (2016) Frequencies of UGT14*A (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine. Eur J Drug Metab Pharmacokinet 41:149\u2013155","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3526_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z Hussein","year":"1997","unstructured":"Hussein Z, Posner J (1997) Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 43:457\u2013465","journal-title":"Br J Clin Pharmacol"},{"key":"3526_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2217\/pgs.12.78","volume":"13","author":"D Chatzistebanidis","year":"2012","unstructured":"Chatzistebanidis D, Georgiou I, Kyritsis AP, Markoula S (2012) Functional impact and prevalence of polymorphisms involved in the hepatic glucurondiation of valproic acid. Pharmacogeonimcs 13:1055\u20131071","journal-title":"Pharmacogeonimcs"},{"key":"3526_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","volume":"60","author":"GD Anderson","year":"1996","unstructured":"Anderson GD, Cau MK, Gidal BE, Harris SJ, Levi RH, Lai AA et al (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 60:145\u2013156","journal-title":"Clin Pharmacol Ther"},{"key":"3526_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/00007691-200210000-00009","volume":"24","author":"MI Mataringa","year":"2002","unstructured":"Mataringa MI, May TW, Rambeck B (2002) Does lamotrigine influence valproate concentrations. Ther Drug Monit 24:632\u2013636","journal-title":"Ther Drug Monit"},{"key":"3526_CR29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bcp.13510","volume":"84","author":"J Methaneethorn","year":"2018","unstructured":"Methaneethorn J (2018) A systematic review of population pharmacokinetics of valproic acide. Br J Clin Pharmacol 84:816\u2013834","journal-title":"Br J Clin Pharmacol"},{"key":"3526_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","volume":"34","author":"M Lovri\u0107","year":"2012","unstructured":"Lovri\u0107 M, Bo\u017eina N, Hajn\u0161ek S, Rojni\u0107 Kuzman M, Spori\u0161 D, Lali\u0107 Z et al (2012) Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit 34:518\u2013525","journal-title":"Ther Drug Monit"},{"key":"3526_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/clpt.2012.46","volume":"92","author":"T Haslemo","year":"2012","unstructured":"Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Elisasson E (2012) UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther 92:221\u2013227","journal-title":"Clin Pharmacol Ther"},{"key":"3526_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/pan\/mpr025","volume":"20","author":"J Hainmueller","year":"2012","unstructured":"Hainmueller J (2012) Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal 20:25\u201346","journal-title":"Polit Anal"},{"key":"3526_CR33","unstructured":"Greifer N (2022) WeightIt: weighting for covariate balance in observational studies. https:\/\/ngreifer.github.io\/WeightIt\/, https:\/\/github.com\/ngreifer\/WeightIt"},{"key":"3526_CR34","unstructured":"R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"3526_CR35","first-page":"295","volume-title":"The effect","author":"N Huntington-Klein","year":"2022","unstructured":"Huntington-Klein N (2022) The effect. CRC Press, Boca Raton, USA, pp 295\u2013297"},{"key":"3526_CR36","unstructured":"Goodrich B, Gabry J, Ali I, Brilleman S (2022) rstanarm: Bayesian applied regression modeling via Stan. R package version 2.21.3.\u00a0https:\/\/mc-stan.org\/rstanarm\/"},{"issue":"1","key":"3526_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/1471-2105-8-428","volume":"8","author":"TR Gaunt","year":"2007","unstructured":"Gaunt TR, Rodr\u00edguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool \u201cCubeX.\u201d BMC Bioinformatics 8(1):428. https:\/\/doi.org\/10.1186\/1471-2105-8-428","journal-title":"BMC Bioinformatics"},{"key":"3526_CR38","doi-asserted-by":"publisher","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15:291\u2013303. https:\/\/doi.org\/10.1002\/pds.1200","DOI":"10.1002\/pds.1200"},{"key":"3526_CR39","doi-asserted-by":"publisher","unstructured":"Heine D (2021). The episensr package: basic sensitivity analysis of epidemiological results.\u00a0https:\/\/doi.org\/10.5281\/zenodo.4554553, R package version 1.1.0, https:\/\/dhaine.github.io\/episensr\/","DOI":"10.5281\/zenodo.4554553"},{"key":"3526_CR40","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/bcp.13646","volume":"84","author":"I Klarica Domjanovi\u0107","year":"2018","unstructured":"Klarica Domjanovi\u0107 I, Lovri\u0107 M, Trkulja V, Petelin-Gad\u017ee \u017d, Ganoci L, \u010caji\u0107 I, Bo\u017eina N (2018) Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsa. Br J Clin Pharmacol 84:2106\u20132119","journal-title":"Br J Clin Pharmacol"},{"key":"3526_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","volume":"27","author":"AE Fohner","year":"2017","unstructured":"Fohner AE, Brackman DJ, Giacomini KM, Altman RB, Klein TE (2017) PharmGKB summary: very important pharmacogene information for ABCG2. Pharmacogenet Genomics 27:420\u2013427","journal-title":"Pharmacogenet Genomics"},{"key":"3526_CR42","doi-asserted-by":"crossref","unstructured":"Bori\u0107-Bilu\u0161i\u0107 A, Bo\u017eina N, Lali\u0107 Z, Lovri\u0107 M, Na\u0111-\u0160kegro S, Penezi\u0107 L, Bari\u0161i\u0107 K, Trkulja V (2022) Loss of function ABCG2 c.421 (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study. Adv Ther (in press)","DOI":"10.21203\/rs.3.rs-2247771\/v1"},{"key":"3526_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz L, Klein TE, Altman RB (2011) Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 21:152\u2013161","journal-title":"Pharmacogenet Genomics"},{"key":"3526_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","volume":"140","author":"V Petrenaite","year":"2018","unstructured":"Petrenaite V, Ohman I, Ekstrom L, Saebye D, Hansen TF, Tomson T, Sabers A (2018) UGT polymorphisms and lamotrigine clearance during pregnancy. Epilepsy Res 140:199\u2013208","journal-title":"Epilepsy Res"},{"key":"3526_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17425255.2021.1876661","volume":"17","author":"H Bruckmueller","year":"2021","unstructured":"Bruckmueller H, Cascorbi I (2021) ABCB1, ABCG2, ABCC1, ABCC2 and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding. Exp Opinion Drug Metab Toxicol 17:369\u2013396","journal-title":"Exp Opinion Drug Metab Toxicol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03526-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T04:06:00Z","timestamp":1689912360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03526-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03526-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2297781\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee at the Zagreb University Hospital Center (approval class: 8.1.-19\/12\u20132, registration number: 02\/21\/AG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided a signed informed consent for participation in the study, i.e., donation of a blood sample for genotyping of pharmacogenes for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided a signed informed consent for participation in the study, including a consent to publish (anonymized) research results in scholarly journals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors meet the ICMJE criteria for authorship.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}]}}